Apr. 29 at 3:22 PM
$NTLA's gene-editing thesis faces a sobering reality check: by commercialization, oral small molecules and generics may erode the addressable market. Moat erosion risk is non-trivial when payers favor cheaper modalities.
Versus established cash generators like
$PFE or
$CVS, NTLA's FCF yield remains deeply negative with binary clinical readouts gating any rerating. Eyes wide open required.